Vericrest Private Wealth Portfolio holdings
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Precision BioSciences
DTIL
|
+$303K |
| 2 |
State Street SPDR Bloomberg Investment Grade Floating Rate ETF
FLRN
|
+$219K |
| 3 |
Invesco Emerging Markets Sovereign Debt ETF
PCY
|
+$208K |
| 4 |
iShares Core Dividend Growth ETF
DGRO
|
+$105K |
| 5 |
State Street SPDR Portfolio S&P 500 High Dividend ETF
SPYD
|
+$96.5K |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
iShares Core US Aggregate Bond ETF
AGG
|
+$1.53M |
| 2 |
PHAS
PhaseBio Pharmaceuticals, Inc. Common Stock
PHAS
|
+$1.39M |
| 3 |
iShares iBoxx $ High Yield Corporate Bond ETF
HYG
|
+$301K |
| 4 |
iShares National Muni Bond ETF
MUB
|
+$168K |
| 5 |
iShares Core S&P 500 ETF
IVV
|
+$144K |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 6.29% |
| 2 | Communication Services | 1.65% |
| 3 | Healthcare | 0.61% |
| 4 | Financials | 0.59% |
| 5 | Consumer Discretionary | 0.28% |
Similar funds
Vericrest Private Wealth's Q2 2022 Portfolio in Review
As of Q2 2022, Vericrest Private Wealth held 40 positions worth $81.5M, down 15% from $96.2M the previous quarter. Its ten largest holdings account for 56% of the portfolio.
Vericrest Private Wealth withdrew a net $3.19M in Q2 2022, closing 1 position and reducing 16 holdings. Its most notable exit was PhaseBio Pharmaceuticals, Inc. Common Stock, an estimated $1.39M position sold in full.
By sector, the portfolio is most concentrated in Technology at 6.3% of assets, down from 6.7% a quarter earlier, followed by Communication Services and Healthcare.
Against the trend, Vericrest Private Wealth opened a new position in Precision BioSciences worth $248K.
- Vericrest Private Wealth's largest Q2 2022 buy was Precision BioSciences: 5,156 shares worth $248K.
- Vericrest Private Wealth added most to State Street SPDR Bloomberg Investment Grade Floating Rate ETF in Q2 2022, an estimated $219K increase.
- Vericrest Private Wealth's biggest Q2 2022 reduction was iShares Core US Aggregate Bond ETF, cutting an estimated $1.53M.
- Vericrest Private Wealth fully exited PhaseBio Pharmaceuticals, Inc. Common Stock in Q2 2022, selling an estimated $1.39M.
- Vericrest Private Wealth's ten largest holdings make up 56% of its $81.5M portfolio in Q2 2022.
- Vericrest Private Wealth opened 1 new position and closed 1 in Q2 2022.
- Vericrest Private Wealth's portfolio value fell 15% quarter-over-quarter to $81.5M.
Based on Vericrest Private Wealth's 13F filing for Q2 2022, filed 15 Aug 2022.